Pharmaceutical Technology, Sep 1, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Sep 1, 2011
Articles
Manufacturing Perspectives: Lessons for Biomanufacturing from Small-Molecule Manufacturing
By Lou Schmukler
A perspective from Pfizer on the lessons from small-molecule manufacturing that can be applied to biomanufacturing.
Building Technology Positions in API Manufacturing
By Patricia Van Arnum
As contract manufacturers and fine-chemical suppliers gather for CPhI/ICSE, effective strategies for technology differentiation are key in an increasingly competitive environment.
FDA's New Process Validation Guidance: Industry Reaction, Questions, and Challenges
By Mike Long , Hal Baseman , Walter D. Henkels
The authors desribe the three-stage approach to validation that is outlined in the new guidance and discuss questions surrounding implementation.
The Determination and Control of Genotoxic Impurities in APIs
By V. Gangadhar , Y. Pardha Saradhi , R. Rajavikram
The authors provide an overview of methods for the quantitative determination of genotoxic impurities (GTIs) in active pharmaceutical ingredients.
Sample Preparation for Quantitative Metal Impurity Testing
By Gayla Velez
The author examines sample-preparations methods used in inductively coupled plasma–optimal emission spectroscopy for four test metals.
Achieving Containment in High-Potency Manufacturing: A Case Study for Solid Dosage Manufacturing
A Q&A with Joe Cascone, director of potent pharmaceutical development at Metrics, moderated by Patricia Van Arnum. Discussion of the key considerations made in facility design, equipment selection, and operations to achieve desired levels of containment.
A Supplier's Role in Ensuring and Improving Excipient Quality
By Frithjof Holtz , Najib Sehat
Excipients are the hidden champions of drug development—no API works consistently without the right excipient. Pharmaceutical excipients, however, require stringent quality management. This article discusses how the supplier of pharmaceutical raw materials should take a central role in ensuring excipient quality.
Addressing Ways to Improve Supply-Chain Security: A Perspective from Pfizer
A Q&A with Brian Johnson, senior director of supply chain security at Pfizer, moderated by Patricia Van Arnum. Part of a special Ingredients issue.
Atypical Actives Gain Attention
By Angie Drakulich
Clarifying GMPs for excipients used as actives.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here